Member Info for crumbs

As has been mentioned the original need to get the dosage down came from an outside 'vaccine manager' who told Lindy moditope would be impractical otherwise... hence Amplivant and 100 fold dose reduction... then there was the niggle with getting it to be a manufacturable product now over come.... then tox testing- done,its safe... then patents.... It is scancells protected IP and not something anyone else could just copy and knock off as its totally novel with new processes needed to create it.... Well done team science let us hope Mellman is in contact already :)

I've asked Cliff about this in the past and he certainly does not discount doing a modi1 deal pre-clinical indeed it to me sounded like it was something there were 'talks' going on about.... has it all been about getting the product fully clinically ready and with patent protection well I'm sure many big players would want that before justifying a deal... this now is a product that is ready to go into trial... with up to 14 targets! wowzers in hard to treat ... in fact terminal patients... To me, it has to be now very attractive... We will of course in time find out if that is the case

Exactly a partnership deal on modi1 on the 4 trial targets plus possibly giving the partner further exclusive favourable options on all other potential targets if it proves itself in the clinic... That is how most small bios do it it is how BioNtech are doing it etc... and yes scancells pipeline is a potential pharma all by itself with almost all cancer targets covered in various disease stages from early to late..... It is why values pre-deal/s is just a waste of time and you are better looking at deals being done.... and deals being done in this sphere are massive..... And yes Merck did not wake up one day knowing the value of Keytruda yet they certainly would not part with it now would they and that is just a product not a platform of potential keytrudas

Certainly, be a need for new treatments and trials in the coming months:

'Cancer Research UK published analysis on June 1 that warned around 2.4 million people in the UK are still waiting for cancer screening, further tests or cancer treatment.

Delays to cancer screening have had the biggest impact on this total, with a backlog of around 2.1 million people left waiting for breast, bowel or cervical screening. During this time, 3,800 cancers would normally be diagnosed through screening.

Cancer Research estimated the shortfalls in screening, referrals and treatment compared to what it would normally expect to see over a ten-week period. The treatment figures were estimated for the UK based on data for England.

Urgent cancer referrals, often known as the two week wait, have been severely impacted with up to 290,000 people missing out on further testing, which would normally catch up to 20,300 cancers in the same time period.

Cancer Research also warned there is a growing backlog of treatment to catch up on, with up to 12,750 fewer patients receiving surgery, 6,000 fewer for chemotherapy and 2,800 fewer receiving radiotherapy since lockdown began.'

https://www.express.co.uk/news/uk/1298392/cancer-news-uk-treatment-screening-referrals-patient-backlog-nhs-coronavirus-latest

Cars yes they have always said there is interest in moditope and CH has never ruled out a deal on modi1 so... fingers crossed as I think that would be the ideal a partner for the first moditope product to go into trial... Also we know the trial targets have had a few changes ... and now are up to 4 targets from 3.... an added expense that but maybe someone else will pay it? who knows but yeah now we are ripe for such a deal with the product finalised the science around moditope more and more understood and proven preclinical data compelling ( in human blood too) the tox testing done and no issues manufacture ready and patented.

BTW says a great deal about the capabilities of team science scancell that they have indeed overcome the challenges to produce a totally novel product that is now ready for manufacture. I'm very happy and not a little relieved with today's news after that earlier niggle ... They have done it!

To the clinic has been a challenge a challenge unforeseen when it was first discovered although not in the clinic yet we now have a clinically viable product one that could change the face of cancer treatment forever also as we know the patents are coming into place so this a very attractive fully owned by Scancell platform......Values ? well no one can explain to us why Kite and Juno got taken out for a combined value of over $18 billion .. And who can put a pricetag on Keytruda!!?? Mercks Golden Goose..... That is the area moditopes potential values lie.....

Chester well in mice the bulkiest tumour loads allowed are dissolving in 2 days of a therapeutic dose..... Not saying that would be the case in humans but on a therapeutic dose if the moditope mechanism is triggered then those cytotoxic CD4 T cells would be going to work so you would expect to see a noticeable effect very soon ...

Yeah is it 15 lab staff we have?..... I forget off my head but some of them are ex-students and possibly for social distancing purposes some of the less senior and vital staff have not been in the labs since lockdown... You would think if there was a real effect on scancells operations we would have had an RNS and we didn't no we got an RNS saying they were busy working on a Covid vaccine lol

Yes, the Sky piece was, I'm sure Lindy well especially due to Covidity and a core few have been working non stop. .. we saw a couple of others and Poulam seemed to all still be working but maybe not all staff were .... We never had an RNS to say what impact the lockdown had...

BTW what that maybe indicates to me is... scancell staff were indeed possibly furloughed or at least not in the labs... that may not mean all staff of course

Doc Kim of spin does it again Inovio bag themselves a sweet $71million of funds
https://www.sharecast.com/news/international-companies/inovio-secures-71m-funding-boost-for-potential-covid-19-vaccine--7549416.html

Yes the scancell labs are at the Uni

No, but CH has said earlier this year he expects scancell to get one of those later this year... so that is a start... any deal can come from any tech from any platform any time it is just we know Avidimab is not going to be trialled by scancell the others are (hopefully lol)

Trinity values scancell as a no-deal/s company once a deal is done let's say on a Glycan Mab with Avidimab against one cancer target then we get real valuations we would know what a company values that tech at and from that could work out further deal potentials... same with ImmunoBody and moditope.... Trinity we all know would bring out a new report fresh after any deal on any tech with a brand new valuation ....

All about the depth and potential of the platforms and them being able to attract pharma.... If modi 1 indeed goes into trial in 4 targets and then shows an immune response in at least 50% of patients and that then translates into real survival benefit and indeed potentially in a significant number with complete disease clearance then with possibly a few Avidimab/Glycans deals TCR deal and ImmunoBody progress £8 quid and beyond then becomes very possible... especially as we know modi1 results would not take years indeed once full therapeutic dosing occurs the picture of how potent it may be would happen fast....

My hope now for the coming months of 2020 would be yes Covidity gets backing....Yes SCIB1 combo trial finds a patient to dose and some in USA too....Yes CRUK do something that smell like a trial with SCIB2.... Yes our first Avidimab deal arrives followed by others ... Yes BioNTech do the TCR deal ...Yes modi1 manufacture is sorted and trial begins by the end of year.

Reality is not all that will happen but surely some of it will and if it all did ... woo hoo.... I'd also personally prefer modi1 to be going into trial with a partner as that's the way most bios do it and with modi2/3 following the IP dilution would in my opinion be worth it.

Personally I just liked the logo and am in for a tenner a share - looking to be in a few months for that :)

'So Why would Pharmas be Interested In anything else the Co produces '
Well there are 4 collaborators already looking at scancell tech with end result if they like what they see they will do deal/s

Ruck surely your 2 is a big YES if it works it has to be worth money considering the conditions it is targeting ... Can it attract money before a trial seems to be the problem... As you're right we know to run the modi1 trial plus if the SCIB1 combo ever gets a patient in its now supposedly running trial is going to be expensive... what at least 10 mil maybe more seeing as modi1 now has 4 trial targets plus keeping the lights on funds..... I hope these recently released scientific papers are attracting the right attention :) having said that you would think interested parties would be in on all the latest data via NDA's

Boom notice he did it with his I believe now wife Özlem Türeci who seems to be kept out the picture
https://www.labiotech.eu/interviews/ozlem-tureci-cancer-immunotherapy/

I'm not one for conspiracy theories and certainly when I got involved in buying scancell shares I never thought Lindy being female had any bearing at all!.... now I begin to wonder